Research Project

Project Title:	AD(H)PKD - Evaluating ADPKD in the era of tolvaptan
Project Type:	Registry Adjunct biobank: DNA, Serum, Urine
Disease group(s):	AD structural kidney disorders
Project Summary:	Approval of Tolvaptan in Europe by the EMA as the first targeted therapy of autosomal-dominant polycystic kidney disease (ADPKD) based on the findings of the TEMPO 3:4 trial is a milestone in the treatment of this disease. After the significant benefit on eGFR in TEMPO 3:4 and 4:4 more data on this therapy regarding crucial questions in the real-life setting would be highly valuable. In order to address these questions we set up AD(H)PKD - a prospective cohort study - in 2015 which is going to follow up ADPKD patients that are evaluated for a potential therapy with tolvaptan for 10 years.
Lead principal investigator(s):	Roman-Ulrich Mueller, Cologne Franziska Grundmann, Cologne
Co-investigator(s):	Thomas Benzing, Cologne Volker Burst, Cologne
Project Period:	11/2015 - 12/2027
Sponsors:	Industry, Local resources
Project web page:	https://www.adpkd.org/
ClinicalTrials.gov:	NCT02497521